Daily Briefing for October 21, 2026

Show Notes

AI model estimates cancer patients' survival from a single face photo

The voices on this episode are generated, and so is the script, from the day's post at Physician in the Loop. Every fact in the post links to its source.

Read the post and its sources

Get the free email briefing

Mass General Brigham researchers reported Oct. 19 that an AI model trained on more than 40 million face photographs predicted survival in cancer patients, sorting them into risk groups whose mortality differed more than threefold.

The study, published in The Lancet Digital Health, tested the model in two independent cancer cohorts, and the authors said a face photo could help with risk stratification when other biomarkers are unavailable. No prospective clinical use has been reported. Separately, the Food and Drug Administration finalized guidance on how drugmakers label apps sold for use with prescription drugs, Radical Numerics said phages designed by its AI model were given to a patient with a drug-resistant infection, and Intuitive reported that da Vinci procedures grew about 14% in the third quarter.

In this episode

• AI model trained on 40 million face photos sorts cancer patients by survival risk, Lancet Digital Health study finds
• FDA finalizes guidance on when apps sold with prescription drugs belong in the drug's prescribing information
• Radical Numerics says phages designed by its AI model were given to a patient with an antibiotic-resistant infection
• Intuitive says da Vinci procedures grew about 14% in the third quarter and places 546 more systems
• Home and virtual supportive oncology program tied to 10.4% fewer admissions among 5,432 Rhode Island cancer patients

What is Physician in the Loop?

How technological innovation is changing medicine for patients and the people who practice on the front lines.

Voice 1: This is Physician in the Loop, the daily briefing on AI in medicine. It's Wednesday, October 21st, 2026.

Voice 1: Researchers at Mass General Brigham say an AI model trained on 40 million face photographs sorted cancer patients into risk groups whose mortality differed more than threefold.

Voice 2: Threefold, just from a photo. How does that actually work?

Voice 1: The model, called FAHR-Face, was fine-tuned into two tools. One, FAHR-FaceAge, estimates biological age, with a mean error of about 5 years on public datasets. The other, FAHR-FaceSurvival, was trained on about 34,000 photographs of patients with cancer.

Voice 2: And that's where the threefold difference comes from?

Voice 1: Yes. Patients in the highest-risk quartile had more than triple the mortality of the lowest quartile, even after adjusting for clinical prognostic factors, and it held up in a second, independent cohort. The study ran in The Lancet Digital Health.

Voice 2: Do the two tools look at the same part of the face?

Voice 1: No, they draw on different facial regions, and combining them improved accuracy further.

Voice 2: So is this heading toward actual clinical use?

Voice 1: Not yet. Dr. Raymond Mak, a radiation oncologist and the corresponding author, said the aim is to support treatment decisions, “rather than replace physician judgment.” The health system has also filed a provisional patent application on facial health algorithms.

Voice 2: No prospective clinical use reported, in other words. Just the retrospective result for now.

Voice 1: The FDA had a different kind of announcement, about apps sold alongside prescription drugs.

Voice 2: What did the agency actually decide?

Voice 1: It finalized guidance on when software paired with a drug belongs in the drug's prescribing information. If the app is tied to a device used with the drug, like one paired with an inhaler, it generally should be described there.

Voice 2: What about standalone apps, the dose reminders and coaching tools?

Voice 1: Those only belong in the prescribing information if the drugmaker shows they're essential to safe and effective use, or deliver a meaningful clinical benefit. Otherwise, the content most companion apps show users will be treated as promotional labeling.

Voice 2: That's a real line to have to defend.

Voice 1: Jared Seehafer, the FDA's deputy commissioner for technology, said companion apps “are quickly moving beyond simple dose reminders toward tools that adapt to each patient.”

Voice 2: A smaller company made its own announcement this week, about phages instead of apps.

Voice 1: Radical Numerics says phages designed by its AI model, Omnii-1, were given to a patient with an antibiotic-resistant infection.

Voice 2: Did it actually work?

Voice 1: The company says the phage cocktail cleared the patient's resistant bacterial isolate in laboratory testing before it was given through a physician-led compassionate-use pathway. It calls this the first clinical use of AI-designed phages.

Voice 2: What aren't they telling us?

Voice 1: A lot. The company didn't name the bacterium, the hospital, or the treating physicians, and didn't disclose the patient's clinical course or outcome.

Voice 2: So we don't even know if the patient got better.

Voice 1: Right. The company itself says one patient can't establish safety or efficacy, that the therapies aren't approved for broader use, and that no paper on the case has been published.

Voice 2: A different kind of oncology story came out of Rhode Island this week, about keeping people out of the hospital rather than treating them once they're there.

Voice 1: What's the program?

Voice 2: Daymark Health's home and virtual supportive oncology program, launched with Blue Cross and Blue Shield of Rhode Island across 20 oncology practices. It was tied to about 10% fewer hospital admissions among more than 5,400 cancer patients.

Voice 1: And the cost side?

Voice 2: Spending came in about 8% lower than projected, or $789 per patient per month.

Voice 1: Projected against what, exactly?

Voice 2: Against trends built from two prior years of claims, not a randomized control group. The authors themselves say this shows an association, not causation, and the findings were presented as an ASCO abstract.

Voice 1: A real number, with a real asterisk attached to how it was measured.

Voice 2: Before we go, something to watch.

Voice 1: The HIMSS AI in Healthcare Forum opens in San Diego on October 22nd, running two days.

Voice 2: What's actually on the agenda?

Voice 1: Governance, policy, and implementation, the vendor and CIO view of what's being rolled out next.

Voice 2: Worth watching whether any of today's tools, the face model, the companion apps, the phages, come up as examples of what that governance is supposed to catch.

Voice 1: Sources and corrections are at physicianintheloop.org, where you can sign up for the free email briefing. This briefing was read by AI voices.